Comparative Pharmacology
Head-to-head clinical analysis: NITRO IV versus NITROLINGUAL PUMPSPRAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITRO IV versus NITROLINGUAL PUMPSPRAY.
NITRO IV vs NITROLINGUAL PUMPSPRAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase cGMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase and increasing cyclic guanosine monophosphate (cGMP), leading to vasodilation of peripheral arteries and veins. This reduces preload and afterload, decreasing myocardial oxygen demand.
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
1-2 sprays sublingually at onset of angina; may repeat every 5 minutes up to 3 doses in 15 minutes. Prophylaxis: 1 spray 5-10 minutes before activity.
None Documented
None Documented
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
Terminal elimination half-life of nitroglycerin is 1–4 minutes; however, clinical hemodynamic effects last longer due to active metabolites and tissue distribution.
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Renal excretion of inactive metabolites (nitrate ions) accounts for approximately 80% of elimination; biliary/fecal excretion is minimal (less than 5%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator